Literature DB >> 16212571

Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment.

G Ficarra1, F Beninati, I Rubino, A Vannucchi, G Longo, P Tonelli, G Pini Prato.   

Abstract

BACKGROUND/AIM: Osteonecrosis of the jaws is being increasingly reported in patients with bone metastasis from a variety of solid tumours and disseminated multiple myeloma receiving intra-venous bisphosphonates. The signs and symptoms that may occur before the appearance of clinical evident osteonecrosis include changes in the health of periodontal tissues, non-healing mucosal ulcers, loose teeth and unexplained soft-tissue infection. A series of nine periodontally involving patients showing osteonecrosis of the jaws that appeared following the intra-venous use of bisphosphonates is reported.
MATERIAL AND METHODS: Nine consecutive patients with osteonecrosis of the jaws were prospectically studied. Patients' past medical histories and the drugs that they had received for their malignant disease were systematically documented. Clinical, histopathological and radiographic features and proposal for treatment modalities of osteonecrosis are also reported.
RESULTS: Of the nine patients (six women and three men) observed, all had osteonecrosis in the mandible; two had maxillary involvement as well. All nine patients had a history of extraction of periodontally hopeless teeth preceding the onset of osteonecrosis. In two patients, the lesions also appeared in edentulous areas spontaneously. All the patients had received intra-venous bisphosphonates as treatment for their disseminated haematological neoplasms or metastatic bone disease. The duration of bisphosphonate therapy at presentation ranged from 10 to 70 months (median: 33 months).
CONCLUSIONS: Jaw osteonecrosis appears to be associated with the intra-venous use of bisphosphonates. Dental professionals should be aware of this potentially serious complication in periodontal patients receiving long-term treatment with bisphosphonates. Copyright (c) Blackwell Munksgaard, 2005.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16212571     DOI: 10.1111/j.1600-051X.2005.00842.x

Source DB:  PubMed          Journal:  J Clin Periodontol        ISSN: 0303-6979            Impact factor:   8.728


  37 in total

1.  Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons.

Authors:  Toshiyuki Yoneda; Hiroshi Hagino; Toshitsugu Sugimoto; Hiroaki Ohta; Shunji Takahashi; Satoshi Soen; Akira Taguchi; Satoru Toyosawa; Toshihiko Nagata; Masahiro Urade
Journal:  J Bone Miner Metab       Date:  2010-03-24       Impact factor: 2.626

2.  Legal liability in bisphosphonate-related osteonecrosis of the jaw.

Authors:  L Lo Russo; D Ciavarella; C Buccelli; O Di Fede; G Campisi; L Lo Muzio; G Pellegrino; P Di Lorenzo
Journal:  Br Dent J       Date:  2014-09       Impact factor: 1.626

3.  Tolerability of intravenous pamidronate for the treatment of osteoporosis and other metabolic osteopathies: A retrospective analysis.

Authors:  Marcelo Sarli; Rodolfo Spivacow; Viviana Pedroarias; Emilio J A Roldán; José R Zanchetta
Journal:  Curr Ther Res Clin Exp       Date:  2007-01

Review 4.  Regulation of bone remodeling by vitamin K2.

Authors:  V D Myneni; E Mezey
Journal:  Oral Dis       Date:  2017-04-05       Impact factor: 3.511

Review 5.  Drugs, medications and periodontal disease.

Authors:  P A Heasman; F J Hughes
Journal:  Br Dent J       Date:  2014-10       Impact factor: 1.626

6.  Spontaneous osteonecrosis of the jaws in the maxilla of mice on antiresorptive treatment: a novel ONJ mouse model.

Authors:  Rafael Scaf de Molon; Simon Cheong; Olga Bezouglaia; Sarah M Dry; Flavia Pirih; Joni Augusto Cirelli; Tara L Aghaloo; Sotirios Tetradis
Journal:  Bone       Date:  2014-08-02       Impact factor: 4.398

7.  Periapical disease and bisphosphonates induce osteonecrosis of the jaws in mice.

Authors:  Ben Kang; Simon Cheong; Thawinee Chaichanasakul; Olga Bezouglaia; Elisa Atti; Sarah M Dry; Flavia Q Pirih; Tara L Aghaloo; Sotirios Tetradis
Journal:  J Bone Miner Res       Date:  2013-07       Impact factor: 6.741

Review 8.  Host-response therapeutics for periodontal diseases.

Authors:  William V Giannobile
Journal:  J Periodontol       Date:  2008-08       Impact factor: 6.993

9.  Osteonecrosis of the jaws caused by bisphosphonates: evaluation of a new therapeutic approach using the Er:YAG laser.

Authors:  Francesca Angiero; Carolina Sannino; Roberto Borloni; Rolando Crippa; Stefano Benedicenti; George E Romanos
Journal:  Lasers Med Sci       Date:  2009-03-11       Impact factor: 3.161

10.  Biphosphonates-related osteonecrosis of the jaw: Clinical and physiopathological considerations.

Authors:  Alberto Borgioli; Christian Viviani; Marco Duvina; Leila Brancato; Giuseppe Spinelli; Maria Luisa Brandi; Paolo Tonelli
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.